Maxygen Licenses Dengue Vaccine Programme to sanofi pasteur

By Business Review Editor

Pharma Deals Review: Vol 2008 Issue 91 (Table of Contents)

Published: 8 Jan-2008

DOI: 10.3833/pdr.v2008.i91.237     ISSN: 1756-7874

Section: Licensing

Fulltext:

Abstract

Maxygen entered into licensing agreement with Sanofi Pasteur to develop and commercialize dengue vaccines using Maxygen’s proprietary dengue virus antigen technology...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details